Anuh Pharma Ltd - 506260 - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2026, Recommendation Of Final Dividend, If Any, And Consideration Of AGM Notice For The Financial Year 2025-26.
Anuh Pharma's Board of Directors will meet on May 20, 2026. The agenda includes the consideration and approval of the audited financial results for the quarter and year ended March 31, 2026, and a recommendation for dividend for FY26.
May 15 2026 20:05:00
Anuh Pharma Limited
Anuh Pharma has secured WHO Prequalification for its Amodiaquine Hydrochloride API. This approval enables the company to supply the anti-malarial ingredient to international markets, including WHO-procured and donor-funded programs, strengthening its global market position.
May 04 2026 21:05:00
Anuh Pharma Ltd - 506260 - Announcement Under Regulation 30 (LODR) - Updates
Anuh Pharma Ltd has secured World Health Organization (WHO) Prequalification (PQ) approval for its Amodiaquine Hydrochloride API. This approval significantly expands the company's market reach to international and WHO-procured anti-malarial programs, strengthening its position as a key API supplier.
May 04 2026 21:05:00
Anuh Pharma Limited
Anuh Pharma opened a special window for the dematerialization of physical shares, adhering to SEBI's January 30, 2026 Circular. This initiative specifically addresses transfer requests lodged before April 1, 2019, that were previously rejected or unattended due to documentation deficiencies.
Apr 17 2026 11:04:00
Read More